CASI Pharmaceuticals Temettü

Temettü kriter kontrolleri 0/6

CASI Pharmaceuticals şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

0.2%

Geri Alım Getirisi

Toplam Hissedar Getirisi	0.2%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü güncellemeleri

Recent updates

CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

May 21

Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%

Mar 12

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%

Dec 18

Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?

May 26

Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts

Aug 14

Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?

May 25

Did CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Insiders Buy Up More Shares?

Mar 16

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: CASI şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: CASI şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

CASI Pharmaceuticals Piyasaya Karşı Temettü Getirisi

CASI temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (CASI)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.5%
Sektör Ortalaması (Biotechs)	2.2%
Analist tahmini (CASI) (3 yıla kadar)	n/a

Önemli Temettü: CASI şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, CASI şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: CASI şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: CASI herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

CASI Pharmaceuticals Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

CASI Pharmaceuticals, Inc. (NasdaqCM:CASI) announces an Equity Buyback for $10 million worth of its shares.

Recent updates

CASI Pharmaceuticals, Inc. Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia

CASI Pharmaceuticals, Inc. Announces Change of Senior Management Positions

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Shareholder dilution

CASI Pharmaceuticals, Inc. Appoints Daniel Lang as CFO

CASI Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding from VR Adviser, LLC, Foresite Capital Management, LLC, Panacea Venture Management Co., Ltd.

CASI Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Consensus revenue estimates fall by 67%

CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

First quarter 2024 earnings: EPS and revenues miss analyst expectations

No longer forecast to breakeven

CASI Pharmaceuticals Receives FDA Clearance on the Investigational New Drug (IND) Application for CID-103 in Immune Thrombocytopenia

New minor risk - Profitability

CASI Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 20, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investors Don't See Light At End Of CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Tunnel And Push Stock Down 26%

CASI Pharmaceuticals Report Positive Interim Phase 1 Data for BI-1206 in the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma in China

CASI Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 20, 2024

Casi Pharmaceuticals Announces First Dose of Folotyn in China

CASI Pharmaceuticals, Inc. Announces Resignation of Fuqiang Zhang as Chief Commercial Officer

CASI Pharmaceuticals, Inc. Appoints of Mr. Huang Hai as the Global Chief Commercial Officer

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Held Back By Insufficient Growth Even After Shares Climb 33%

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Forecast to breakeven in 2024

We're Keeping An Eye On CASI Pharmaceuticals' (NASDAQ:CASI) Cash Burn Rate

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

CASI Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 01, 2023

CASI Pharmaceuticals, Inc.(NasdaqCM:CASI) dropped from S&P TMI Index

Consensus EPS estimates upgraded to US$1.88 loss, revenue downgraded

Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Invest In Growth?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

CASI Pharmaceuticals, Inc. Announces Clinical Trial Application Approval for CB-5339 in Patients with Multiple Myeloma in China

Consensus forecasts updated

Forecast to breakeven in 2024

Price target decreased to US$18.33

Insufficient new directors

Casi to sell stake in Juventas to Jiadao Gongcheng for ~RMB240.87M

CASI Pharmaceuticals and BioInvent Announces Dosing of First Patient in BI-1206 Phase 1 Clinical Trial for the Treatment of Relapsed/Refractory Non-Hodgkin's Lymphoma in China

Consensus forecasts updated

Price target decreased to US$22.67

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

CASI Pharmaceuticals Q2 2022 Earnings Preview

CASI Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 12, 2022

Chairman & CEO recently bought US$273k worth of stock

Price target decreased to US$37.00

Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?

No longer forecast to breakeven

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

CASI Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target increased to US$4.67

Insufficient new directors

CASI Pharmaceuticals, Inc., Annual General Meeting, May 25, 2022

Consensus forecasts updated

Full year 2021 earnings: EPS misses analyst expectations

Price target increased to US$4.67

CASI Pharmaceuticals, Inc. Provides Revenue Guidance for the Year 2022

CASI Pharmaceuticals Receives Nasdaq Deficiency Notice

Forecast to breakeven in 2024

CASI Pharmaceuticals, Inc. (NasdaqCM:CASI) announces an Equity Buyback for $10 million worth of its shares.

Casi Pharmaceuticals and Bioinvent Announce CTA Approval for Clinical Study of Bi-1206 in NHL in China

Chairman & CEO recently bought US$394k worth of stock

Third quarter 2021 earnings released: US$0.073 loss per share (vs US$0.14 loss in 3Q 2020)

Chairman & CEO recently bought US$614k worth of stock

Second quarter 2021 earnings released: US$0.05 loss per share (vs US$0.086 loss in 2Q 2020)

Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts

Price target increased to US$4.45

Consensus revenue estimates increase to US$28.5m

Casi Pharmaceuticals, Inc. Revises Revenue Guidance for the Year 2021

CASI Pharmaceuticals, Inc.(NasdaqCM:CASI) dropped from Russell 3000E Value Index

Casi Pharmaceuticals Announces Dosing of First Patient of Cid-103 in Phase 1 Clinical Trial for Relapsed or Refractory Multiple Myeloma

Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.085 loss in 1Q 2020)

Forecast to breakeven in 2024